Klinická farmakologie a farmacie – 3/2018

www.klinickafarmakologie.cz  / Klin Farmakol Farm 2019; 33(3): 41–45 / KLINICKÁ FARMAKOLOGIE A FARMACIE 45 KAZUISTIKY Ceftolozan/tazobaktam v terapii multifokální infekce způsobené multirezistentním kmenem Pseudomonas aeruginosa u těžce popáleného pacienta LITERATURA 1. Decraene V, Ghebrehewet S, Dardamissis E, et al. An out­ break of multidrug‑resistant Pseudomonas aeruginosa in a burns service in the North of England: challenges of infecti­ on prevention and control in a complex setting. J Hosp Infect. 2018 Dec; 100(4): e239–e245. doi: 10.1016/j.jhin.2018. 07. 012. 2. Slaviero L, Avruscio G, Vindigni V, Tocco‑Tussardi I. Antisep­ tics for burns: a review of the evidence. Ann Burns Fire Disas­ ters. 2018 Sep 30; 31(3): 198–203. 3. Wang Y, Beekman J, Hew J, Jackson S, Issler‑Fisher AC, Pa­ rungao R, Lajevardi SS, Li Z, Maitz PKM. Burn injury: Challen­ ges and advances in burn wound healing, infection, pain and scarring. Adv Drug Deliv Rev. 2018 Jan 1; 123: 3–17. doi: 10.1016/j.addr.2017. 09. 018. 4. Cho JC, Fiorenza MA, Estrada SJ. Ceftolozane/Tazobactam: A Novel Cephalosporin/β‑Lactamase Inhibitor Combination. Pharmacotherapy.2015Jul;35(7):701–715.doi:10.1002/phar.1609. 5. Larson KB, Patel YT, Willavize S, Bradley JS, Rhee EG, Caro L, Rizk ML. Ceftolozane/tazobactam population pharmacokine­ tics and dose selection for further clinical evaluation in pe­ diatric patients with complicated urinary tract or complica­ ted intraabdominal infections. Antimicrob Agents Chemo­ ther. 2019 Apr 8. pii: AAC.02578-18. doi: 10.1128/AAC.02578-18. 6. Pfaller MA, Shortridge D, Sader HS, CastanheiraM, FlammRK. Ceftolozane/tazobactamactivityagainstdrug‑resistantEntero­ bacteriaceaeandPseudomonasaeruginosacausinghealthcare‑associated infections in the Asia‑Pacific region (minus Chi­ na, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013–2015). Int J Antimicrob Agents. 2018 Feb; 51(2): 181–189. doi: 10.1016/j.ijantimicag.2017. 09. 016. 7. Shortridge D, Castanheira M, Pfaller MA, Flamm RK. Ceftolozane‑Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015. Antimicrob Agents Chemother. 2017 Jun 27; 61(7). pii: e00465– 17. doi: 10.1128/AAC.00465-17. 8. KalilAC,MeterskyML,KlompasM,etal.ManagementofAdul­ ts With Hospital‑acquired and Ventilator‑associated Pneumo­ nia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin In­ fect, DiS. 2016 Sep 1; 63(5): e61–e111. doi: 10.1093/cid/ciw353. 9. SousaDominguezA,Perez‑RodríguezMT,NodarA,Martinez‑Lamas L, Perez‑Landeiro A, Crespo Casal M. Successful tre­ atmentofMDRPseudomonasaeruginosaskinandsoft‑tissue in­ fectionwithceftolozane/tazobactam.JAntimicrobChemother. 2017 Apr 1; 72(4): 1262–1263. doi: 10.1093/jac/dkw526. 10. Castaldo N, Givone F, Peghin M, Righi E, Sartor A, Ba­ ssetti M. Multidrug‑resistant Pseudomonas aeruginosa skin and soft‑tissue infection successfully treated with ceftoloza­ ne/tazobactam. J Glob Antimicrob Resist. 2017 Jun; 9: 100– 102. doi: 10.1016/j.jgar.2017. 02. 012. 11. DietlB,Sánchez I,ArcenillasP,etal.Ceftolozane/tazobactam inthetreatmentofosteomyelitisandskinandsoft‑tissue infecti­ onsduetoextensivelydrug‑resistantPseudomonasaeruginosa: clinical andmicrobiological outcomes. Int J Antimicrob Agents. 2018 Mar; 51(3): 498–502. doi: 10.1016/j.ijantimicag.2017. 11. 003. 12. Gentile I, Buonomo AR, Maraolo AE, Scotto R, De Zo­ ttis F, Di Renzo G, Borgia G. Successful treatment of post‑surgical osteomyelitis caused by XDR Pseudomonas ae­ ruginosa with ceftolozane/tazobactam monotherapy. J Antimicrob Chemother. 2017 Sep 1; 72(9): 2678–2679. doi: 10.1093/jac/dkx172. 13. Skoglund E, Ledesma KR, Lasco TM, Tam VH. Ceftoloza­ ne/tazobactam activity against meropenem‑non‑susceptible Pseudomonas aeruginosa bloodstream infection isolates. J Glob Antimicrob Resist. 2017 Dec; 11: 154–155. doi: 10.1016/j. jgar.2017. 10. 016. 14. Aitken SL, Kontoyiannis DP, DePombo AM, Bhatti MM, Tverdek FP, Gettys SC, Nicolau DP, Nunez CA. Use of Cef­ tolozane/Tazobactam in the Treatment of Multidrug‑resistant Pseudomonas aeruginosa Bloodstream Infecti­ on in a Pediatric Leukemia Patient. Pediatr Infect Dis J. 2016 Sep; 35(9): 1040–1042. doi: 10.1097/INF.0000000000001228.